In the phase 3 SPARTAN trial, the addition of apalutamide to androgen-deprivation therapy (ADT) improved median metastasis-free survival (MFS) and progression-free survival (PFS) in non-metastatic castration-resistant prostate cancer (nmCRPC), compared with placebo . Now, overall survival data are mature, and this was also significantly improved in patients treated with apalutamide.
ADT is the mainstay of treatment for metastatic prostate cancer. ADT is also an important part of care for many men with non-metastatic prostate cancer. However, although ADT is initially effective, castration-resistant disease eventually develops in almost all men with prostate cancer.
The phase 3 SPARTAN trial evaluated the effect of adding the non-steroidal anti-androgen agent apalutamide to ADT in patients with nmCRPC. A total of 1,207 patients were 2:1 randomised to apalutamide (240 mg once daily) or placebo. At the primary endpoint analysis, apalutamide showed t...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« ARAMIS final OS and nmCRPC safety outcomes Next Article
Novel drug for kidney cancers/VHL patients »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.